Compare DLTH & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTH | ONCY |
|---|---|---|
| Founded | 1989 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 113.4M |
| IPO Year | 2015 | 2002 |
| Metric | DLTH | ONCY |
|---|---|---|
| Price | $4.43 | $0.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $7.33 |
| AVG Volume (30 Days) | 243.8K | ★ 1.2M |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $565,184,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.80 | $2,505.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $0.77 |
| 52 Week High | $5.09 | $1.51 |
| Indicator | DLTH | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 57.76 | 48.75 |
| Support Level | $2.80 | $0.90 |
| Resistance Level | $5.09 | $1.06 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 46.22 | 44.73 |
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.